Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

Hdl Handle:
http://hdl.handle.net/10147/322896
Title:
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications
Authors:
Godman, Brian; Petzold, Max; Bennett, Kathleen; Bennie, Marion; Bucsics, Anna; Finlayson, Alexander E; Martin, Andrew; Persson, Marie; Piessnegger, Jutta; Raschi, Emanuel; Simoens, Steven; Zara, Corinne; Barbui, Corrado
Citation:
Godman B et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine. 2014 Jun 13;12(1):98
Issue Date:
13-Jun-2014
URI:
http://dx.doi.org/10.1186/1741-7015-12-98; http://hdl.handle.net/10147/322896
Abstract:
Abstract Background Generic atypical antipsychotic drugs offer health authorities opportunities for considerable savings. However, schizophrenia and bipolar disorders are complex diseases that require tailored treatments. Consequently, generally there have been limited demand-side measures by health authorities to encourage the preferential prescribing of generics. This is unlike the situation with hypertension, hypercholaesterolaemia or acid-related stomach disorders.The objectives of this study were to compare the effect of the limited demand-side measures in Western European countries and regions on the subsequent prescribing of risperidone following generics; to utilise the findings to provide future guidance to health authorities; and where possible, to investigate the utilisation of generic versus originator risperidone and the prices for generic risperidone. Methods Principally, this was a segmented regression analysis of retrospective time-series data of the effect of the various initiatives in Belgium, Ireland, Scotland and Sweden following the introduction of generic risperidone. The study included patients prescribed at least one atypical antipsychotic drug up to 20 months before and up to 20 months after generic risperidone. In addition, retrospective observational studies were carried out in Austria and Spain (Catalonia) from 2005 to 2011 as well as one English primary care organisation (Bury Primary Care Trust (PCT)). Results There was a consistent steady reduction in risperidone as a percentage of total selected atypical antipsychotic utilisation following generics. A similar pattern was seen in Austria and Spain, with stable utilisation in one English PCT. However, there was considerable variation in the utilisation of generic risperidone, ranging from 98% of total risperidone in Scotland to only 14% in Ireland. Similarly, the price of generic risperidone varied considerably. In Scotland, generic risperidone was only 16% of pre-patent loss prices versus 72% in Ireland. Conclusion Consistent findings of no increased prescribing of risperidone post generics with limited specific demand-side measures suggests no ‘spillover’ effect from one class to another encouraging the preferential prescribing of generic atypical antipsychotic drugs. This is exacerbated by the complexity of the disease area and differences in the side-effects between treatments. There appeared to be no clinical issues with generic risperidone, and prices inversely reflected measures to enhance their utilisation.
Item Type:
Article
Language:
en
Keywords:
MENTAL AND BEHAVIOURAL DISORDER; DRUGS; PRESCRIBING
Local subject classification:
DRUGS, ANTIPSYCHOTIC

Full metadata record

DC FieldValue Language
dc.contributor.authorGodman, Brianen_GB
dc.contributor.authorPetzold, Maxen_GB
dc.contributor.authorBennett, Kathleenen_GB
dc.contributor.authorBennie, Marionen_GB
dc.contributor.authorBucsics, Annaen_GB
dc.contributor.authorFinlayson, Alexander Een_GB
dc.contributor.authorMartin, Andrewen_GB
dc.contributor.authorPersson, Marieen_GB
dc.contributor.authorPiessnegger, Juttaen_GB
dc.contributor.authorRaschi, Emanuelen_GB
dc.contributor.authorSimoens, Stevenen_GB
dc.contributor.authorZara, Corinneen_GB
dc.contributor.authorBarbui, Corradoen_GB
dc.date.accessioned2014-07-15T09:39:45Z-
dc.date.available2014-07-15T09:39:45Z-
dc.date.issued2014-06-13-
dc.identifier.citationGodman B et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Medicine. 2014 Jun 13;12(1):98en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1741-7015-12-98-
dc.identifier.urihttp://hdl.handle.net/10147/322896-
dc.description.abstractAbstract Background Generic atypical antipsychotic drugs offer health authorities opportunities for considerable savings. However, schizophrenia and bipolar disorders are complex diseases that require tailored treatments. Consequently, generally there have been limited demand-side measures by health authorities to encourage the preferential prescribing of generics. This is unlike the situation with hypertension, hypercholaesterolaemia or acid-related stomach disorders.The objectives of this study were to compare the effect of the limited demand-side measures in Western European countries and regions on the subsequent prescribing of risperidone following generics; to utilise the findings to provide future guidance to health authorities; and where possible, to investigate the utilisation of generic versus originator risperidone and the prices for generic risperidone. Methods Principally, this was a segmented regression analysis of retrospective time-series data of the effect of the various initiatives in Belgium, Ireland, Scotland and Sweden following the introduction of generic risperidone. The study included patients prescribed at least one atypical antipsychotic drug up to 20 months before and up to 20 months after generic risperidone. In addition, retrospective observational studies were carried out in Austria and Spain (Catalonia) from 2005 to 2011 as well as one English primary care organisation (Bury Primary Care Trust (PCT)). Results There was a consistent steady reduction in risperidone as a percentage of total selected atypical antipsychotic utilisation following generics. A similar pattern was seen in Austria and Spain, with stable utilisation in one English PCT. However, there was considerable variation in the utilisation of generic risperidone, ranging from 98% of total risperidone in Scotland to only 14% in Ireland. Similarly, the price of generic risperidone varied considerably. In Scotland, generic risperidone was only 16% of pre-patent loss prices versus 72% in Ireland. Conclusion Consistent findings of no increased prescribing of risperidone post generics with limited specific demand-side measures suggests no ‘spillover’ effect from one class to another encouraging the preferential prescribing of generic atypical antipsychotic drugs. This is exacerbated by the complexity of the disease area and differences in the side-effects between treatments. There appeared to be no clinical issues with generic risperidone, and prices inversely reflected measures to enhance their utilisation.-
dc.language.isoenen
dc.subjectMENTAL AND BEHAVIOURAL DISORDERen_GB
dc.subjectDRUGSen_GB
dc.subjectPRESCRIBINGen_GB
dc.subject.otherDRUGS, ANTIPSYCHOTICen_GB
dc.titleCan authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implicationsen_GB
dc.typeArticleen
dc.language.rfc3066en-
dc.rights.holderBrian Godman et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2014-06-27T19:04:47Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.